Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 4/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893036 | 0.87 | ACACB (0.44) | ACHE | |
| SCHEMBL16480420 | 0.85 | SORD (0.54) | SORDACHEHRH4HRH3HTR3A | |
| SCHEMBL9891831 | 0.82 | SORD (0.46) | SORDACHEHRH4HRH3HTR3A | |
| SCHEMBL9893112 | 0.75 | HRH4 (0.38) | HRH4HRH3 | |
| SCHEMBL9893154 | 0.72 | ACACB (0.45) | SORD | |
| SCHEMBL9893053 | 0.71 | SORD (0.37) | SORD | |
| SCHEMBL9891836 | 0.70 | ACACB (0.43) | — | |
| SCHEMBL9892342 | 0.70 | ACACB (0.48) | — | |
| SCHEMBL9892045 | 0.70 | CNR2 (0.46) | CYP2D6 | |
| SCHEMBL1088608 | 0.69 | HRH4 (0.59) | SORDHRH4HRH3ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | SORD 4445/4885ACHE 1832/4885HRH4 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.